Oncology

Study finds greater rate of opioid prescribing among cancer survivors 10 or more years past their cancer diagnosis.

Baby boomer hepatitis C virus screening rates spiked when a prompt in their electronic health records reminded a primary care provider to recommend testing.

Understudied gene provides insight into how liver cancer cells gain the nutrition necessary to proliferate.

A first-in-class molecule was found to inhibit primary and recurrent breast cancer.

The novel strategy could be more effective and less toxic than current chemotherapy drugs treating alternative lengthening telomere cancers.

Carolyn Choate journeys 300 miles in a kayak to honor the pharmacologist who created the lifesaving aromatase inhibitor.

Top news of the week from Specialty Pharmacy Times.

Managing chronic pain after a cancer diagnosis remains a challenge.

The new compounds may lead to a highly effective, next-line treatment for estrogen receptor-positive breast cancer.

Study is the first to provide evidence that proton-coupled amino acid transporters can be elevated in prostate cancer.

Age and tumor type most associated with initial insurance denial of cancer treatment, study finds.

Gene editing tool reveals why some patients with cancer fail to respond to immunotherapy.

Several breakthrough cancer drugs were approved in the first half of 2017.

In some cases, chemotherapy can spur cancer cells to spread to other parts of the body.

Paclitaxel chemotherapy may turn on a stress gene that allows cancer cells to escape from the primary tumor.

The receptor helps drive estrogen-receptor positive mammary tumor progression in low estrogen environments.

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Study identifies previously unknown properties of gold to release anti-cancer drugs inside of tumors.

Young black women are more likely to have aggress breast cancer subtypes than white women.

Triple drug regimen effectively cured patients with hepatitis C virus after they failed to respond to a combination of two oral direct-acting antivirals.

Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions, discusses the expanding role of educational patient support programs in oncology.

Elderly patients with hepatitis C are typically difficult to treat due to poor tolerability and suboptimal response to interferon-based regimens.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.

Targeted radiotherapy for breast cancer may improve overall quality of life and reduces side effects.

Top news of the day from across the health care landscape.

The risk of gallbladder cancer was highest in women with a history of periodontal disease.

Studying HER2-positive breast cancer at the cellular level may yield new treatments.

An estimated 2.7 million Americans have hepatitis C, too many for specialists to be the sole provider of anti-HCV therapy.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.